Inventor · disambiguated record
Olga Vasiljeva
Also filed as: VASILJEVA OLGA
32 granted patents·14 pending applications·325 citations·filing 2012–2025
97Inventor score
Files withCYTOMX THERAPEUTICS INC42INST JOZEF STEFAN1INSTITUTE OF STRENGTH PHYSICS AND MAT SCIENCE OF SIBERIAN BRANCH RUSSIAN ACADEMY OF SCIENCES ISPMS S1J STEFAN INST1VASILJEVA OLGA1
Top patents by PatentIndex Score
46 records- 0197US10709799B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Jul 14, 2020·10 cites·31 claims
- 0297US10138272B2Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Nov 27, 2018·31 cites·43 claims
- 0397US9889211B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Feb 13, 2018·29 cites·52 claims
- 0497US9562073B2Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Feb 7, 2017·32 cites·51 claims
- 0597US9127053B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Sep 8, 2015·39 cites·33 claims
- 0697US9120853B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Sep 1, 2015·52 cites·43 claims
- 0796US9545442B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jan 17, 2017·19 cites·57 claims
- 0895US11028126B2Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Jun 8, 2021·8 cites·54 claims
- 0995US10669339B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Jun 2, 2020·10 cites·44 claims
- 1095US10301380B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2017·Granted May 28, 2019·17 cites·29 claims
- 1195US9487590B2Activatable antibodies that bind interleukin-6 receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Nov 8, 2016·15 cites·35 claims
- 1294US11867695B2Compositions and methods for detecting protease activity in biological systemsCYTOMX THERAPEUTICS INC·Filed 2021·Granted Jan 9, 2024·2 cites·26 claims
- 1394US10336824B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jul 2, 2019·16 cites·48 claims
- 1493US11890354B2Activatable antibodies that bind epidermal growth factor receptor and methods thereofCYTOMX THERAPEUTICS INC·Filed 2020·Granted Feb 6, 2024·2 cites·16 claims
- 1593US9688748B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jun 27, 2017·11 cites·39 claims
- 1691US11046759B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jun 29, 2021·4 cites·58 claims
- 1791US11035859B2Compositions and methods for detecting protease activity in biological systemsCYTOMX THERAPEUTICS INC·Filed 2019·Granted Jun 15, 2021·3 cites·37 claims
- 1890US12502439B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Granted Dec 23, 2025·0 cites·20 claims
- 1990US10261083B2Compositions and methods for detecting protease activity in biological systemsCYTOMX THERAPEUTICS INC·Filed 2014·Granted Apr 16, 2019·14 cites·20 claims
- 2086US12459999B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Granted Nov 4, 2025·0 cites·8 claims
- 2186US12049505B2Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Jul 30, 2024·4 cites·23 claims
- 2285US2024337658A1Compositions and methods for detecting protease activity in biological systemsCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2384US10611845B2Activatable antibodies that bind interleukin-6 receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Apr 7, 2020·2 cites·35 claims
- 2483US2024150402A1Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2582US11174316B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Nov 16, 2021·1 cites·19 claims
- 2681US2024150478A1Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2781US2024084022A1Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2879US11548943B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Jan 10, 2023·0 cites·9 claims
- 2979US11472875B1Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Oct 18, 2022·0 cites·11 claims
- 3078US11548944B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Jan 10, 2023·0 cites·10 claims
- 3176US11884746B2Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Jan 30, 2024·0 cites·6 claims
- 3275US2024239904A1Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3374US2022298245A1Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3473US11814410B2Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Nov 14, 2023·0 cites·28 claims
- 3567US9827337B2Cathepsin-binding compounds bound to a carrier and their diagnostic useVASILJEVA OLGA·Filed 2012·Granted Nov 28, 2017·3 cites·3 claims
- 3664US2020339694A1Activatable antibodies that bind interleukin-6 receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3763US2019367589A1Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3861US2015087810A1Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use ThereofCYTOMX THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 3957US10105318B2Low-dimensional structures of organic and/or inorganic substances and use thereofINSTITUTE OF STRENGTH PHYSICS AND MAT SCIENCE OF SIBERIAN BRANCH RUSSIAN ACADEMY OF SCIENCES ISPMS S·Filed 2015·Granted Oct 23, 2018·1 cites·14 claims
- 4055US10668175B2Cathepsin-binding compounds bound to a carrier and their diagnostic useJ STEFAN INST·Filed 2017·Granted Jun 2, 2020·0 cites·6 claims
- 4151US2022226514A1Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugatesCYTOMX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4250US2024384323A1Method for determining protease activity in a biological sampleCYTOMX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4348US2025215095A1Protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4447US2020405890A1Positron emission tomography imaging of activatable binding polypeptides and related compositions thereofCYTOMX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4540US2014186268A1Oxide Ferrimagnetics with Spinel Structure Nanoparticles and Iron Oxide Nanoparticles, Biocompatible Aqueous Colloidal Systems Comprising Nanoparticles, Ferriliposomes, and Uses ThereofINST JOZEF STEFAN·Filed 2014·Application pending·0 cites
- 4639US12498367B2Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Dec 16, 2025·0 cites·34 claims
Join the waitlist — get patent alerts
Get an alert when Olga Vasiljeva files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →